Long-Term Follow-up of Subjects Who Were Treated With ST-920

Sangamo Therapeutics

Status: Invitation-only

Conditions: Fabry Disease; Fabry Disease, Cardiac Variant

Treatments: Biological: ST-920

Study type: Observational

Funder types: Industry

Identifiers

NCT05039866

ST-920-LT01

Details and patient eligibility

About

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

Full description

Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with ST-920 in the clinical study ST-920-201. All subjects dosed in the study who completed at least 52 weeks post-infusion follow-up in their primary protocol will be offered to participate. Subjects who enroll will be monitored for a total of up to 5 years following ST-920 infusion.

Enrollment: 48 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects who received ST-920 therapy in a separate parent trial
• Subjects who have consented to participate in this LTFU study.

Exclusion criteria

-This study has no exclusion criteria

Trial design

48 participants in 1 patient group

Subjects who received ST-920

Description:

Subjects who received ST-920 in a separate parent trial

Treatment:

Biological: ST-920